nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—colon cancer	0.435	1	CbGaD
Sulindac—ALB—Irinotecan—colon cancer	0.0457	0.271	CbGbCtD
Sulindac—ALB—Fluorouracil—colon cancer	0.0439	0.261	CbGbCtD
Sulindac—SLC22A6—Methotrexate—colon cancer	0.0284	0.169	CbGbCtD
Sulindac—CYP1A2—Fluorouracil—colon cancer	0.0262	0.156	CbGbCtD
Sulindac—ALB—Methotrexate—colon cancer	0.0242	0.144	CbGbCtD
Sulindac—MAPK3—endothelium—colon cancer	0.00605	0.0611	CbGeAlD
Sulindac—MAPK3—blood vessel—colon cancer	0.00558	0.0563	CbGeAlD
Sulindac—AKR1B1—embryo—colon cancer	0.00459	0.0464	CbGeAlD
Sulindac—AKR1B1—epithelium—colon cancer	0.00375	0.0378	CbGeAlD
Sulindac—AKR1B1—smooth muscle tissue—colon cancer	0.00361	0.0365	CbGeAlD
Sulindac—AKR1B1—renal system—colon cancer	0.00347	0.0351	CbGeAlD
Sulindac—MAPK3—embryo—colon cancer	0.00333	0.0336	CbGeAlD
Sulindac—AKR1B1—lymphoid tissue—colon cancer	0.00288	0.0291	CbGeAlD
Sulindac—AKR1B1—digestive system—colon cancer	0.00285	0.0288	CbGeAlD
Sulindac—MAPK3—epithelium—colon cancer	0.00271	0.0274	CbGeAlD
Sulindac—AKR1B1—bone marrow—colon cancer	0.00263	0.0265	CbGeAlD
Sulindac—MAPK3—smooth muscle tissue—colon cancer	0.00262	0.0264	CbGeAlD
Sulindac—MAPK3—renal system—colon cancer	0.00252	0.0254	CbGeAlD
Sulindac—AKR1B1—vagina—colon cancer	0.00252	0.0254	CbGeAlD
Sulindac—ALB—gall bladder—colon cancer	0.0025	0.0253	CbGeAlD
Sulindac—PPARD—lymphoid tissue—colon cancer	0.00227	0.0229	CbGeAlD
Sulindac—PPARD—digestive system—colon cancer	0.00224	0.0226	CbGeAlD
Sulindac—AKR1B1—liver—colon cancer	0.00212	0.0214	CbGeAlD
Sulindac—MAPK3—lymphoid tissue—colon cancer	0.00209	0.0211	CbGeAlD
Sulindac—MAPK3—digestive system—colon cancer	0.00207	0.0209	CbGeAlD
Sulindac—PPARD—vagina—colon cancer	0.00198	0.02	CbGeAlD
Sulindac—MAPK3—bone marrow—colon cancer	0.0019	0.0192	CbGeAlD
Sulindac—MAPK3—vagina—colon cancer	0.00182	0.0184	CbGeAlD
Sulindac—PPARD—liver—colon cancer	0.00167	0.0169	CbGeAlD
Sulindac—PTGS1—endothelium—colon cancer	0.00164	0.0166	CbGeAlD
Sulindac—AKR1B1—lymph node—colon cancer	0.00163	0.0164	CbGeAlD
Sulindac—PTGS2—endothelium—colon cancer	0.00157	0.0159	CbGeAlD
Sulindac—MAPK3—liver—colon cancer	0.00154	0.0155	CbGeAlD
Sulindac—PTGS1—blood vessel—colon cancer	0.00152	0.0153	CbGeAlD
Sulindac—PTGS2—blood vessel—colon cancer	0.00145	0.0146	CbGeAlD
Sulindac—PTGS2—gall bladder—colon cancer	0.00136	0.0138	CbGeAlD
Sulindac—PPARD—lymph node—colon cancer	0.00128	0.0129	CbGeAlD
Sulindac—MAPK3—lymph node—colon cancer	0.00118	0.0119	CbGeAlD
Sulindac—PTGS2—embryo—colon cancer	0.000864	0.00873	CbGeAlD
Sulindac—CYP1A1—epithelium—colon cancer	0.00084	0.00848	CbGeAlD
Sulindac—CYP1A2—renal system—colon cancer	0.00079	0.00798	CbGeAlD
Sulindac—CYP1A1—renal system—colon cancer	0.000779	0.00787	CbGeAlD
Sulindac—PTGS1—epithelium—colon cancer	0.000738	0.00745	CbGeAlD
Sulindac—ALB—liver—colon cancer	0.000734	0.00741	CbGeAlD
Sulindac—PTGS1—smooth muscle tissue—colon cancer	0.000711	0.00718	CbGeAlD
Sulindac—PTGS2—epithelium—colon cancer	0.000705	0.00712	CbGeAlD
Sulindac—PTGS1—renal system—colon cancer	0.000684	0.00691	CbGeAlD
Sulindac—PTGS2—smooth muscle tissue—colon cancer	0.000679	0.00686	CbGeAlD
Sulindac—PTGS2—renal system—colon cancer	0.000654	0.00661	CbGeAlD
Sulindac—CYP1A2—digestive system—colon cancer	0.000648	0.00654	CbGeAlD
Sulindac—CYP1A1—digestive system—colon cancer	0.000639	0.00645	CbGeAlD
Sulindac—CYP1A1—vagina—colon cancer	0.000564	0.0057	CbGeAlD
Sulindac—ALB—lymph node—colon cancer	0.000563	0.00568	CbGeAlD
Sulindac—PTGS1—digestive system—colon cancer	0.000561	0.00567	CbGeAlD
Sulindac—PTGS2—lymphoid tissue—colon cancer	0.000543	0.00549	CbGeAlD
Sulindac—PTGS2—digestive system—colon cancer	0.000536	0.00542	CbGeAlD
Sulindac—PTGS1—vagina—colon cancer	0.000496	0.00501	CbGeAlD
Sulindac—PTGS2—bone marrow—colon cancer	0.000495	0.005	CbGeAlD
Sulindac—CYP1A2—liver—colon cancer	0.000483	0.00487	CbGeAlD
Sulindac—CYP1A1—liver—colon cancer	0.000476	0.00481	CbGeAlD
Sulindac—PTGS2—vagina—colon cancer	0.000474	0.00479	CbGeAlD
Sulindac—Depressed level of consciousness—Methotrexate—colon cancer	0.000464	0.00361	CcSEcCtD
Sulindac—Aplastic anaemia—Methotrexate—colon cancer	0.000451	0.00351	CcSEcCtD
Sulindac—Flushing—Irinotecan—colon cancer	0.000449	0.0035	CcSEcCtD
Sulindac—Alopecia—Vincristine—colon cancer	0.000439	0.00342	CcSEcCtD
Sulindac—Coma—Methotrexate—colon cancer	0.000439	0.00342	CcSEcCtD
Sulindac—Chills—Irinotecan—colon cancer	0.000434	0.00338	CcSEcCtD
Sulindac—Ecchymosis—Methotrexate—colon cancer	0.000434	0.00338	CcSEcCtD
Sulindac—Arrhythmia—Irinotecan—colon cancer	0.000432	0.00337	CcSEcCtD
Sulindac—Gynaecomastia—Methotrexate—colon cancer	0.00043	0.00335	CcSEcCtD
Sulindac—Alopecia—Irinotecan—colon cancer	0.000428	0.00333	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000422	0.00328	CcSEcCtD
Sulindac—Flatulence—Irinotecan—colon cancer	0.000415	0.00323	CcSEcCtD
Sulindac—Gastritis—Capecitabine—colon cancer	0.000414	0.00323	CcSEcCtD
Sulindac—Arrhythmia—Fluorouracil—colon cancer	0.000414	0.00323	CcSEcCtD
Sulindac—Muscular weakness—Capecitabine—colon cancer	0.000413	0.00322	CcSEcCtD
Sulindac—Alopecia—Fluorouracil—colon cancer	0.00041	0.00319	CcSEcCtD
Sulindac—Anaemia—Vincristine—colon cancer	0.0004	0.00311	CcSEcCtD
Sulindac—PTGS2—liver—colon cancer	0.0004	0.00404	CbGeAlD
Sulindac—Bronchospasm—Capecitabine—colon cancer	0.000398	0.0031	CcSEcCtD
Sulindac—Photosensitivity—Methotrexate—colon cancer	0.000397	0.00309	CcSEcCtD
Sulindac—Sweating increased—Capecitabine—colon cancer	0.000394	0.00307	CcSEcCtD
Sulindac—Ill-defined disorder—Irinotecan—colon cancer	0.000391	0.00305	CcSEcCtD
Sulindac—Anaemia—Irinotecan—colon cancer	0.000389	0.00303	CcSEcCtD
Sulindac—Vertigo—Vincristine—colon cancer	0.000389	0.00303	CcSEcCtD
Sulindac—Hepatic failure—Methotrexate—colon cancer	0.000388	0.00302	CcSEcCtD
Sulindac—Leukopenia—Vincristine—colon cancer	0.000387	0.00302	CcSEcCtD
Sulindac—Pancytopenia—Capecitabine—colon cancer	0.000384	0.00299	CcSEcCtD
Sulindac—Vision blurred—Fluorouracil—colon cancer	0.00038	0.00296	CcSEcCtD
Sulindac—Malaise—Irinotecan—colon cancer	0.00038	0.00296	CcSEcCtD
Sulindac—Vertigo—Irinotecan—colon cancer	0.000379	0.00295	CcSEcCtD
Sulindac—Neutropenia—Capecitabine—colon cancer	0.000378	0.00295	CcSEcCtD
Sulindac—Dysuria—Capecitabine—colon cancer	0.000378	0.00295	CcSEcCtD
Sulindac—Syncope—Irinotecan—colon cancer	0.000378	0.00294	CcSEcCtD
Sulindac—Leukopenia—Irinotecan—colon cancer	0.000377	0.00294	CcSEcCtD
Sulindac—Convulsion—Vincristine—colon cancer	0.000375	0.00292	CcSEcCtD
Sulindac—Hypertension—Vincristine—colon cancer	0.000373	0.00291	CcSEcCtD
Sulindac—Anaemia—Fluorouracil—colon cancer	0.000373	0.00291	CcSEcCtD
Sulindac—Loss of consciousness—Irinotecan—colon cancer	0.00037	0.00288	CcSEcCtD
Sulindac—Dermatitis exfoliative—Methotrexate—colon cancer	0.000369	0.00288	CcSEcCtD
Sulindac—Photosensitivity reaction—Capecitabine—colon cancer	0.000369	0.00288	CcSEcCtD
Sulindac—Myalgia—Vincristine—colon cancer	0.000368	0.00287	CcSEcCtD
Sulindac—Visual disturbance—Methotrexate—colon cancer	0.000368	0.00287	CcSEcCtD
Sulindac—Hyperglycaemia—Capecitabine—colon cancer	0.000365	0.00284	CcSEcCtD
Sulindac—CYP1A1—lymph node—colon cancer	0.000365	0.00369	CbGeAlD
Sulindac—Hypertension—Irinotecan—colon cancer	0.000364	0.00283	CcSEcCtD
Sulindac—Pneumonia—Capecitabine—colon cancer	0.000363	0.00283	CcSEcCtD
Sulindac—Leukopenia—Fluorouracil—colon cancer	0.000361	0.00281	CcSEcCtD
Sulindac—Depression—Capecitabine—colon cancer	0.00036	0.0028	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000358	0.00279	CcSEcCtD
Sulindac—Renal failure—Capecitabine—colon cancer	0.000355	0.00276	CcSEcCtD
Sulindac—Discomfort—Irinotecan—colon cancer	0.000354	0.00276	CcSEcCtD
Sulindac—Neuropathy peripheral—Capecitabine—colon cancer	0.000354	0.00276	CcSEcCtD
Sulindac—Oedema—Vincristine—colon cancer	0.000353	0.00275	CcSEcCtD
Sulindac—Anaphylactic shock—Vincristine—colon cancer	0.000353	0.00275	CcSEcCtD
Sulindac—Jaundice—Capecitabine—colon cancer	0.000352	0.00274	CcSEcCtD
Sulindac—Stomatitis—Capecitabine—colon cancer	0.000352	0.00274	CcSEcCtD
Sulindac—Conjunctivitis—Capecitabine—colon cancer	0.000351	0.00273	CcSEcCtD
Sulindac—Convulsion—Fluorouracil—colon cancer	0.00035	0.00272	CcSEcCtD
Sulindac—Thrombocytopenia—Vincristine—colon cancer	0.000346	0.00269	CcSEcCtD
Sulindac—Haematuria—Capecitabine—colon cancer	0.000344	0.00268	CcSEcCtD
Sulindac—Oedema—Irinotecan—colon cancer	0.000344	0.00268	CcSEcCtD
Sulindac—Anaphylactic shock—Irinotecan—colon cancer	0.000344	0.00268	CcSEcCtD
Sulindac—Chest pain—Fluorouracil—colon cancer	0.000344	0.00268	CcSEcCtD
Sulindac—Myalgia—Fluorouracil—colon cancer	0.000344	0.00268	CcSEcCtD
Sulindac—Hyperhidrosis—Vincristine—colon cancer	0.000341	0.00266	CcSEcCtD
Sulindac—Epistaxis—Capecitabine—colon cancer	0.00034	0.00265	CcSEcCtD
Sulindac—Discomfort—Fluorouracil—colon cancer	0.000339	0.00264	CcSEcCtD
Sulindac—Shock—Irinotecan—colon cancer	0.000338	0.00264	CcSEcCtD
Sulindac—Agranulocytosis—Capecitabine—colon cancer	0.000337	0.00262	CcSEcCtD
Sulindac—Thrombocytopenia—Irinotecan—colon cancer	0.000337	0.00262	CcSEcCtD
Sulindac—Anorexia—Vincristine—colon cancer	0.000337	0.00262	CcSEcCtD
Sulindac—Hyperhidrosis—Irinotecan—colon cancer	0.000332	0.00259	CcSEcCtD
Sulindac—Hypotension—Vincristine—colon cancer	0.00033	0.00257	CcSEcCtD
Sulindac—Anaphylactic shock—Fluorouracil—colon cancer	0.000329	0.00257	CcSEcCtD
Sulindac—Oedema—Fluorouracil—colon cancer	0.000329	0.00257	CcSEcCtD
Sulindac—Anorexia—Irinotecan—colon cancer	0.000328	0.00255	CcSEcCtD
Sulindac—Hepatitis—Capecitabine—colon cancer	0.000324	0.00252	CcSEcCtD
Sulindac—Thrombocytopenia—Fluorouracil—colon cancer	0.000322	0.00251	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Vincristine—colon cancer	0.000322	0.00251	CcSEcCtD
Sulindac—Tachycardia—Fluorouracil—colon cancer	0.000321	0.0025	CcSEcCtD
Sulindac—Hypotension—Irinotecan—colon cancer	0.000321	0.0025	CcSEcCtD
Sulindac—PTGS1—lymph node—colon cancer	0.000321	0.00324	CbGeAlD
Sulindac—Insomnia—Vincristine—colon cancer	0.000319	0.00249	CcSEcCtD
Sulindac—Paraesthesia—Vincristine—colon cancer	0.000317	0.00247	CcSEcCtD
Sulindac—Anorexia—Fluorouracil—colon cancer	0.000314	0.00245	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000314	0.00245	CcSEcCtD
Sulindac—Visual impairment—Capecitabine—colon cancer	0.000312	0.00243	CcSEcCtD
Sulindac—Insomnia—Irinotecan—colon cancer	0.000311	0.00242	CcSEcCtD
Sulindac—Paraesthesia—Irinotecan—colon cancer	0.000309	0.00241	CcSEcCtD
Sulindac—Hypotension—Fluorouracil—colon cancer	0.000308	0.0024	CcSEcCtD
Sulindac—Decreased appetite—Vincristine—colon cancer	0.000307	0.00239	CcSEcCtD
Sulindac—Dyspnoea—Irinotecan—colon cancer	0.000307	0.00239	CcSEcCtD
Sulindac—PTGS2—lymph node—colon cancer	0.000306	0.0031	CbGeAlD
Sulindac—Erythema multiforme—Capecitabine—colon cancer	0.000306	0.00239	CcSEcCtD
Sulindac—Somnolence—Irinotecan—colon cancer	0.000306	0.00238	CcSEcCtD
Sulindac—Fatigue—Vincristine—colon cancer	0.000304	0.00237	CcSEcCtD
Sulindac—Dyspepsia—Irinotecan—colon cancer	0.000303	0.00236	CcSEcCtD
Sulindac—Tinnitus—Capecitabine—colon cancer	0.000302	0.00235	CcSEcCtD
Sulindac—Constipation—Vincristine—colon cancer	0.000302	0.00235	CcSEcCtD
Sulindac—Flushing—Capecitabine—colon cancer	0.000301	0.00234	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.0003	0.00234	CcSEcCtD
Sulindac—Decreased appetite—Irinotecan—colon cancer	0.000299	0.00233	CcSEcCtD
Sulindac—Eosinophilia—Methotrexate—colon cancer	0.000298	0.00232	CcSEcCtD
Sulindac—Insomnia—Fluorouracil—colon cancer	0.000298	0.00232	CcSEcCtD
Sulindac—Fatigue—Irinotecan—colon cancer	0.000296	0.00231	CcSEcCtD
Sulindac—Paraesthesia—Fluorouracil—colon cancer	0.000296	0.0023	CcSEcCtD
Sulindac—Pancreatitis—Methotrexate—colon cancer	0.000295	0.0023	CcSEcCtD
Sulindac—Constipation—Irinotecan—colon cancer	0.000294	0.00229	CcSEcCtD
Sulindac—Dyspnoea—Fluorouracil—colon cancer	0.000294	0.00229	CcSEcCtD
Sulindac—Somnolence—Fluorouracil—colon cancer	0.000293	0.00228	CcSEcCtD
Sulindac—Chills—Capecitabine—colon cancer	0.000291	0.00226	CcSEcCtD
Sulindac—Dyspepsia—Fluorouracil—colon cancer	0.00029	0.00226	CcSEcCtD
Sulindac—Arrhythmia—Capecitabine—colon cancer	0.000289	0.00225	CcSEcCtD
Sulindac—Gastrointestinal pain—Vincristine—colon cancer	0.000289	0.00225	CcSEcCtD
Sulindac—Decreased appetite—Fluorouracil—colon cancer	0.000286	0.00223	CcSEcCtD
Sulindac—Alopecia—Capecitabine—colon cancer	0.000286	0.00223	CcSEcCtD
Sulindac—Pancytopenia—Methotrexate—colon cancer	0.000286	0.00223	CcSEcCtD
Sulindac—Feeling abnormal—Irinotecan—colon cancer	0.000283	0.00221	CcSEcCtD
Sulindac—Dysuria—Methotrexate—colon cancer	0.000282	0.00219	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—colon cancer	0.000282	0.00219	CcSEcCtD
Sulindac—Gastrointestinal pain—Irinotecan—colon cancer	0.000281	0.00219	CcSEcCtD
Sulindac—Body temperature increased—Vincristine—colon cancer	0.000279	0.00217	CcSEcCtD
Sulindac—Flatulence—Capecitabine—colon cancer	0.000278	0.00216	CcSEcCtD
Sulindac—Dysgeusia—Capecitabine—colon cancer	0.000276	0.00215	CcSEcCtD
Sulindac—Photosensitivity reaction—Methotrexate—colon cancer	0.000275	0.00214	CcSEcCtD
Sulindac—Body temperature increased—Irinotecan—colon cancer	0.000272	0.00212	CcSEcCtD
Sulindac—Feeling abnormal—Fluorouracil—colon cancer	0.000271	0.00211	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—colon cancer	0.00027	0.0021	CcSEcCtD
Sulindac—Depression—Methotrexate—colon cancer	0.000268	0.00209	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000266	0.00207	CcSEcCtD
Sulindac—Vision blurred—Capecitabine—colon cancer	0.000266	0.00207	CcSEcCtD
Sulindac—Renal failure—Methotrexate—colon cancer	0.000264	0.00206	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—colon cancer	0.000262	0.00204	CcSEcCtD
Sulindac—Ill-defined disorder—Capecitabine—colon cancer	0.000262	0.00204	CcSEcCtD
Sulindac—Urticaria—Fluorouracil—colon cancer	0.000262	0.00204	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—colon cancer	0.000261	0.00203	CcSEcCtD
Sulindac—Anaemia—Capecitabine—colon cancer	0.000261	0.00203	CcSEcCtD
Sulindac—Body temperature increased—Fluorouracil—colon cancer	0.00026	0.00203	CcSEcCtD
Sulindac—Hypersensitivity—Vincristine—colon cancer	0.00026	0.00203	CcSEcCtD
Sulindac—Sweating—Methotrexate—colon cancer	0.000258	0.00201	CcSEcCtD
Sulindac—Haematuria—Methotrexate—colon cancer	0.000256	0.002	CcSEcCtD
Sulindac—Malaise—Capecitabine—colon cancer	0.000254	0.00198	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—colon cancer	0.000253	0.00197	CcSEcCtD
Sulindac—Vertigo—Capecitabine—colon cancer	0.000253	0.00197	CcSEcCtD
Sulindac—Hypersensitivity—Irinotecan—colon cancer	0.000253	0.00197	CcSEcCtD
Sulindac—Asthenia—Vincristine—colon cancer	0.000253	0.00197	CcSEcCtD
Sulindac—Syncope—Capecitabine—colon cancer	0.000253	0.00197	CcSEcCtD
Sulindac—Leukopenia—Capecitabine—colon cancer	0.000252	0.00197	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—colon cancer	0.000251	0.00195	CcSEcCtD
Sulindac—Palpitations—Capecitabine—colon cancer	0.000249	0.00194	CcSEcCtD
Sulindac—Loss of consciousness—Capecitabine—colon cancer	0.000248	0.00193	CcSEcCtD
Sulindac—Asthenia—Irinotecan—colon cancer	0.000247	0.00192	CcSEcCtD
Sulindac—Hypertension—Capecitabine—colon cancer	0.000243	0.0019	CcSEcCtD
Sulindac—Hypersensitivity—Fluorouracil—colon cancer	0.000243	0.00189	CcSEcCtD
Sulindac—Diarrhoea—Vincristine—colon cancer	0.000242	0.00188	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—colon cancer	0.000241	0.00188	CcSEcCtD
Sulindac—Chest pain—Capecitabine—colon cancer	0.00024	0.00187	CcSEcCtD
Sulindac—Arthralgia—Capecitabine—colon cancer	0.00024	0.00187	CcSEcCtD
Sulindac—Myalgia—Capecitabine—colon cancer	0.00024	0.00187	CcSEcCtD
Sulindac—Discomfort—Capecitabine—colon cancer	0.000237	0.00185	CcSEcCtD
Sulindac—Diarrhoea—Irinotecan—colon cancer	0.000235	0.00183	CcSEcCtD
Sulindac—Dizziness—Vincristine—colon cancer	0.000233	0.00182	CcSEcCtD
Sulindac—Pruritus—Fluorouracil—colon cancer	0.000233	0.00182	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—colon cancer	0.000232	0.00181	CcSEcCtD
Sulindac—Oedema—Capecitabine—colon cancer	0.00023	0.00179	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—colon cancer	0.000228	0.00178	CcSEcCtD
Sulindac—Dizziness—Irinotecan—colon cancer	0.000227	0.00177	CcSEcCtD
Sulindac—Shock—Capecitabine—colon cancer	0.000226	0.00176	CcSEcCtD
Sulindac—Diarrhoea—Fluorouracil—colon cancer	0.000225	0.00176	CcSEcCtD
Sulindac—Thrombocytopenia—Capecitabine—colon cancer	0.000225	0.00176	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—colon cancer	0.000225	0.00175	CcSEcCtD
Sulindac—Tachycardia—Capecitabine—colon cancer	0.000225	0.00175	CcSEcCtD
Sulindac—Vomiting—Vincristine—colon cancer	0.000224	0.00175	CcSEcCtD
Sulindac—Rash—Vincristine—colon cancer	0.000223	0.00173	CcSEcCtD
Sulindac—Hyperhidrosis—Capecitabine—colon cancer	0.000222	0.00173	CcSEcCtD
Sulindac—Dermatitis—Vincristine—colon cancer	0.000222	0.00173	CcSEcCtD
Sulindac—Headache—Vincristine—colon cancer	0.000221	0.00172	CcSEcCtD
Sulindac—Anorexia—Capecitabine—colon cancer	0.000219	0.00171	CcSEcCtD
Sulindac—Vomiting—Irinotecan—colon cancer	0.000219	0.0017	CcSEcCtD
Sulindac—Dizziness—Fluorouracil—colon cancer	0.000218	0.0017	CcSEcCtD
Sulindac—Rash—Irinotecan—colon cancer	0.000217	0.00169	CcSEcCtD
Sulindac—Dermatitis—Irinotecan—colon cancer	0.000217	0.00169	CcSEcCtD
Sulindac—Chills—Methotrexate—colon cancer	0.000216	0.00169	CcSEcCtD
Sulindac—Headache—Irinotecan—colon cancer	0.000215	0.00168	CcSEcCtD
Sulindac—Hypotension—Capecitabine—colon cancer	0.000215	0.00168	CcSEcCtD
Sulindac—Alopecia—Methotrexate—colon cancer	0.000213	0.00166	CcSEcCtD
Sulindac—Nausea—Vincristine—colon cancer	0.00021	0.00163	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00021	0.00163	CcSEcCtD
Sulindac—Vomiting—Fluorouracil—colon cancer	0.000209	0.00163	CcSEcCtD
Sulindac—Insomnia—Capecitabine—colon cancer	0.000208	0.00162	CcSEcCtD
Sulindac—Rash—Fluorouracil—colon cancer	0.000208	0.00162	CcSEcCtD
Sulindac—Dermatitis—Fluorouracil—colon cancer	0.000207	0.00162	CcSEcCtD
Sulindac—Paraesthesia—Capecitabine—colon cancer	0.000207	0.00161	CcSEcCtD
Sulindac—Headache—Fluorouracil—colon cancer	0.000206	0.00161	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—colon cancer	0.000206	0.0016	CcSEcCtD
Sulindac—Dyspnoea—Capecitabine—colon cancer	0.000205	0.0016	CcSEcCtD
Sulindac—Nausea—Irinotecan—colon cancer	0.000204	0.00159	CcSEcCtD
Sulindac—Dyspepsia—Capecitabine—colon cancer	0.000203	0.00158	CcSEcCtD
Sulindac—Decreased appetite—Capecitabine—colon cancer	0.0002	0.00156	CcSEcCtD
Sulindac—Fatigue—Capecitabine—colon cancer	0.000198	0.00155	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—colon cancer	0.000198	0.00154	CcSEcCtD
Sulindac—Constipation—Capecitabine—colon cancer	0.000197	0.00153	CcSEcCtD
Sulindac—Nausea—Fluorouracil—colon cancer	0.000196	0.00152	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—colon cancer	0.000195	0.00152	CcSEcCtD
Sulindac—Anaemia—Methotrexate—colon cancer	0.000194	0.00151	CcSEcCtD
Sulindac—Feeling abnormal—Capecitabine—colon cancer	0.00019	0.00148	CcSEcCtD
Sulindac—Malaise—Methotrexate—colon cancer	0.000189	0.00147	CcSEcCtD
Sulindac—Vertigo—Methotrexate—colon cancer	0.000189	0.00147	CcSEcCtD
Sulindac—Gastrointestinal pain—Capecitabine—colon cancer	0.000188	0.00147	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—colon cancer	0.000188	0.00146	CcSEcCtD
Sulindac—Urticaria—Capecitabine—colon cancer	0.000183	0.00142	CcSEcCtD
Sulindac—Body temperature increased—Capecitabine—colon cancer	0.000182	0.00142	CcSEcCtD
Sulindac—Convulsion—Methotrexate—colon cancer	0.000182	0.00142	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—colon cancer	0.000179	0.00139	CcSEcCtD
Sulindac—Chest pain—Methotrexate—colon cancer	0.000179	0.00139	CcSEcCtD
Sulindac—Myalgia—Methotrexate—colon cancer	0.000179	0.00139	CcSEcCtD
Sulindac—Discomfort—Methotrexate—colon cancer	0.000177	0.00138	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—colon cancer	0.000171	0.00133	CcSEcCtD
Sulindac—Hypersensitivity—Capecitabine—colon cancer	0.00017	0.00132	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—colon cancer	0.000168	0.00131	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—colon cancer	0.000166	0.00129	CcSEcCtD
Sulindac—Asthenia—Capecitabine—colon cancer	0.000165	0.00129	CcSEcCtD
Sulindac—Anorexia—Methotrexate—colon cancer	0.000163	0.00127	CcSEcCtD
Sulindac—Pruritus—Capecitabine—colon cancer	0.000163	0.00127	CcSEcCtD
Sulindac—Hypotension—Methotrexate—colon cancer	0.00016	0.00125	CcSEcCtD
Sulindac—Diarrhoea—Capecitabine—colon cancer	0.000157	0.00123	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000156	0.00122	CcSEcCtD
Sulindac—Insomnia—Methotrexate—colon cancer	0.000155	0.00121	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—colon cancer	0.000154	0.0012	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—colon cancer	0.000153	0.00119	CcSEcCtD
Sulindac—Somnolence—Methotrexate—colon cancer	0.000152	0.00119	CcSEcCtD
Sulindac—Dizziness—Capecitabine—colon cancer	0.000152	0.00119	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—colon cancer	0.000151	0.00117	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—colon cancer	0.000149	0.00116	CcSEcCtD
Sulindac—Fatigue—Methotrexate—colon cancer	0.000148	0.00115	CcSEcCtD
Sulindac—Vomiting—Capecitabine—colon cancer	0.000146	0.00114	CcSEcCtD
Sulindac—Rash—Capecitabine—colon cancer	0.000145	0.00113	CcSEcCtD
Sulindac—Dermatitis—Capecitabine—colon cancer	0.000145	0.00113	CcSEcCtD
Sulindac—Headache—Capecitabine—colon cancer	0.000144	0.00112	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—colon cancer	0.000141	0.0011	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—colon cancer	0.00014	0.00109	CcSEcCtD
Sulindac—Nausea—Capecitabine—colon cancer	0.000137	0.00106	CcSEcCtD
Sulindac—Urticaria—Methotrexate—colon cancer	0.000136	0.00106	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—colon cancer	0.000135	0.00106	CcSEcCtD
Sulindac—Hypersensitivity—Methotrexate—colon cancer	0.000126	0.000983	CcSEcCtD
Sulindac—Asthenia—Methotrexate—colon cancer	0.000123	0.000958	CcSEcCtD
Sulindac—Pruritus—Methotrexate—colon cancer	0.000121	0.000944	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—colon cancer	0.000117	0.000913	CcSEcCtD
Sulindac—Dizziness—Methotrexate—colon cancer	0.000113	0.000883	CcSEcCtD
Sulindac—Vomiting—Methotrexate—colon cancer	0.000109	0.000849	CcSEcCtD
Sulindac—Rash—Methotrexate—colon cancer	0.000108	0.000841	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—colon cancer	0.000108	0.000841	CcSEcCtD
Sulindac—Headache—Methotrexate—colon cancer	0.000107	0.000836	CcSEcCtD
Sulindac—Nausea—Methotrexate—colon cancer	0.000102	0.000793	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR in disease—AKT1—colon cancer	4.48e-05	0.000264	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	4.48e-05	0.000264	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—AKT1—colon cancer	4.48e-05	0.000264	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	4.47e-05	0.000263	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—SRC—colon cancer	4.45e-05	0.000262	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—AKT1—colon cancer	4.44e-05	0.000262	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—AKT1—colon cancer	4.41e-05	0.00026	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—AKT1—colon cancer	4.39e-05	0.000258	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—colon cancer	4.38e-05	0.000258	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—colon cancer	4.37e-05	0.000257	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	4.36e-05	0.000257	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	4.35e-05	0.000256	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—VEGFA—colon cancer	4.33e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—EGFR—colon cancer	4.31e-05	0.000254	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—NRAS—colon cancer	4.28e-05	0.000252	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—AKT1—colon cancer	4.26e-05	0.000251	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—AKT1—colon cancer	4.24e-05	0.00025	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.22e-05	0.000249	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CASP3—colon cancer	4.22e-05	0.000249	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	4.22e-05	0.000249	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	4.15e-05	0.000245	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—KRAS—colon cancer	4.14e-05	0.000244	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCND1—colon cancer	4.11e-05	0.000242	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CTNNB1—colon cancer	4.07e-05	0.00024	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KRAS—colon cancer	4.07e-05	0.00024	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	4.04e-05	0.000238	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CDKN1A—colon cancer	3.98e-05	0.000234	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	3.97e-05	0.000234	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.93e-05	0.000232	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—EGFR—colon cancer	3.9e-05	0.00023	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PPARG—colon cancer	3.89e-05	0.000229	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—AKT1—colon cancer	3.87e-05	0.000228	CbGpPWpGaD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	3.86e-05	0.000228	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—colon cancer	3.86e-05	0.000227	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—PIK3CA—colon cancer	3.8e-05	0.000224	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EP300—colon cancer	3.78e-05	0.000223	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—AKT1—colon cancer	3.75e-05	0.000221	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—PIK3CA—colon cancer	3.74e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—KRAS—colon cancer	3.68e-05	0.000217	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—SRC—colon cancer	3.68e-05	0.000217	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CCND1—colon cancer	3.67e-05	0.000216	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ODC1—colon cancer	3.63e-05	0.000214	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CHST5—colon cancer	3.63e-05	0.000214	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.62e-05	0.000213	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.61e-05	0.000213	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—colon cancer	3.58e-05	0.000211	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDKN1A—colon cancer	3.55e-05	0.000209	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD8A—colon cancer	3.54e-05	0.000209	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—colon cancer	3.54e-05	0.000209	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.54e-05	0.000209	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—colon cancer	3.52e-05	0.000207	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CTNNB1—colon cancer	3.51e-05	0.000207	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—colon cancer	3.46e-05	0.000204	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—EP300—colon cancer	3.38e-05	0.000199	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.34e-05	0.000197	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.34e-05	0.000197	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MYC—colon cancer	3.3e-05	0.000194	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TGFB1—colon cancer	3.29e-05	0.000194	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CCND1—colon cancer	3.28e-05	0.000194	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EP300—colon cancer	3.26e-05	0.000192	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EGFR—colon cancer	3.22e-05	0.00019	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—EP300—colon cancer	3.2e-05	0.000189	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDKN1A—colon cancer	3.18e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—SRC—colon cancer	3.17e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—colon cancer	3.13e-05	0.000185	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—SRC—colon cancer	3.11e-05	0.000184	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CTNNB1—colon cancer	3.1e-05	0.000183	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—colon cancer	3.09e-05	0.000182	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	3.07e-05	0.000181	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—colon cancer	3.06e-05	0.00018	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—AKT1—colon cancer	3.05e-05	0.00018	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—colon cancer	3.05e-05	0.00018	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—colon cancer	3.05e-05	0.00018	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—colon cancer	3.03e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CDKN1A—colon cancer	3.03e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BCL2L1—colon cancer	3.03e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—EP300—colon cancer	3.02e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—colon cancer	3e-05	0.000177	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.97e-05	0.000175	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MYC—colon cancer	2.95e-05	0.000174	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	2.93e-05	0.000173	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	2.91e-05	0.000171	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FGFR3—colon cancer	2.9e-05	0.000171	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EP300—colon cancer	2.88e-05	0.00017	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MYC—colon cancer	2.85e-05	0.000168	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TGFB1—colon cancer	2.84e-05	0.000167	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	2.83e-05	0.000167	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—SRC—colon cancer	2.8e-05	0.000165	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PIK3CA—colon cancer	2.8e-05	0.000165	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TGFB1—colon cancer	2.78e-05	0.000164	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EGFR—colon cancer	2.78e-05	0.000164	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—colon cancer	2.71e-05	0.00016	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—colon cancer	2.7e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Disease—FGFR3—colon cancer	2.67e-05	0.000158	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.65e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—colon cancer	2.63e-05	0.000155	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—colon cancer	2.63e-05	0.000155	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.63e-05	0.000155	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	2.6e-05	0.000153	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—colon cancer	2.59e-05	0.000153	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—colon cancer	2.58e-05	0.000152	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PPARG—colon cancer	2.55e-05	0.00015	CbGpPWpGaD
Sulindac—PPARD—Metabolism—EP300—colon cancer	2.54e-05	0.00015	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.51e-05	0.000148	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EGFR—colon cancer	2.46e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Disease—APC—colon cancer	2.46e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDH1—colon cancer	2.45e-05	0.000144	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PIK3CA—colon cancer	2.37e-05	0.00014	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.35e-05	0.000139	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—colon cancer	2.32e-05	0.000137	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—colon cancer	2.31e-05	0.000136	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—colon cancer	2.29e-05	0.000135	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—colon cancer	2.29e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—colon cancer	2.23e-05	0.000132	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	2.21e-05	0.00013	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—colon cancer	2.19e-05	0.000129	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.18e-05	0.000129	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—colon cancer	2.16e-05	0.000127	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.14e-05	0.000126	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ABCB1—colon cancer	2.14e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—colon cancer	2.13e-05	0.000126	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TYMS—colon cancer	2.1e-05	0.000124	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—colon cancer	1.98e-05	0.000116	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—colon cancer	1.97e-05	0.000116	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—colon cancer	1.97e-05	0.000116	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—colon cancer	1.94e-05	0.000114	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—colon cancer	1.88e-05	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGFR3—colon cancer	1.87e-05	0.00011	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—colon cancer	1.86e-05	0.00011	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.85e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTNNB1—colon cancer	1.81e-05	0.000106	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.81e-05	0.000106	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1A—colon cancer	1.76e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—colon cancer	1.74e-05	0.000103	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.73e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APC—colon cancer	1.72e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—colon cancer	1.72e-05	0.000101	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCB1—colon cancer	1.7e-05	0.0001	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.69e-05	9.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EP300—colon cancer	1.68e-05	9.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—colon cancer	1.67e-05	9.83e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TYMS—colon cancer	1.67e-05	9.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SRC—colon cancer	1.63e-05	9.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1A—colon cancer	1.63e-05	9.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—colon cancer	1.62e-05	9.53e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.62e-05	9.52e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGFR3—colon cancer	1.59e-05	9.37e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—colon cancer	1.57e-05	9.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—colon cancer	1.57e-05	9.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EP300—colon cancer	1.55e-05	9.14e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—EP300—colon cancer	1.54e-05	9.08e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.54e-05	9.07e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—colon cancer	1.54e-05	9.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SRC—colon cancer	1.51e-05	8.89e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—colon cancer	1.51e-05	8.87e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.5e-05	8.84e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SRC—colon cancer	1.5e-05	8.83e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—colon cancer	1.49e-05	8.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—colon cancer	1.48e-05	8.72e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TYMS—colon cancer	1.48e-05	8.72e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—colon cancer	1.46e-05	8.61e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—colon cancer	1.46e-05	8.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—colon cancer	1.46e-05	8.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—colon cancer	1.45e-05	8.55e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—colon cancer	1.44e-05	8.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—colon cancer	1.43e-05	8.44e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.4e-05	8.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—colon cancer	1.37e-05	8.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—colon cancer	1.37e-05	8.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—colon cancer	1.36e-05	8.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—colon cancer	1.35e-05	7.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—colon cancer	1.35e-05	7.96e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TYMS—colon cancer	1.35e-05	7.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—colon cancer	1.35e-05	7.94e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—colon cancer	1.34e-05	7.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—colon cancer	1.32e-05	7.79e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.28e-05	7.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—colon cancer	1.26e-05	7.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—colon cancer	1.25e-05	7.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—colon cancer	1.24e-05	7.32e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—colon cancer	1.24e-05	7.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—colon cancer	1.21e-05	7.14e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—colon cancer	1.18e-05	6.96e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.18e-05	6.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—colon cancer	1.18e-05	6.95e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—colon cancer	1.17e-05	6.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—colon cancer	1.17e-05	6.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—colon cancer	1.15e-05	6.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—colon cancer	1.15e-05	6.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1A—colon cancer	1.14e-05	6.73e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—colon cancer	1.14e-05	6.72e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.14e-05	6.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—colon cancer	1.11e-05	6.55e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—colon cancer	1.1e-05	6.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EP300—colon cancer	1.09e-05	6.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—colon cancer	1.06e-05	6.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SRC—colon cancer	1.06e-05	6.22e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—colon cancer	1.05e-05	6.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—colon cancer	1.05e-05	6.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—colon cancer	1.03e-05	6.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—colon cancer	1.02e-05	5.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—colon cancer	1.01e-05	5.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—colon cancer	1.01e-05	5.95e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—colon cancer	9.92e-06	5.85e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.81e-06	5.78e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—EP300—colon cancer	9.73e-06	5.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1A—colon cancer	9.69e-06	5.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—colon cancer	9.6e-06	5.66e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—colon cancer	9.55e-06	5.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—colon cancer	9.46e-06	5.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—colon cancer	9.44e-06	5.56e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TYMS—colon cancer	9.43e-06	5.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—colon cancer	9.37e-06	5.52e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—colon cancer	9.31e-06	5.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—colon cancer	9.25e-06	5.45e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EP300—colon cancer	9.22e-06	5.43e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SRC—colon cancer	8.97e-06	5.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—colon cancer	8.74e-06	5.15e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—colon cancer	8.63e-06	5.08e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—colon cancer	8.24e-06	4.86e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—colon cancer	8.04e-06	4.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—colon cancer	8.03e-06	4.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—colon cancer	8.02e-06	4.72e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—colon cancer	7.86e-06	4.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—colon cancer	7.77e-06	4.58e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—EP300—colon cancer	7.72e-06	4.55e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—colon cancer	7.51e-06	4.43e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—colon cancer	7.43e-06	4.38e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—colon cancer	7.42e-06	4.38e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.26e-06	4.28e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—colon cancer	7.2e-06	4.24e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—EP300—colon cancer	6.85e-06	4.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—colon cancer	6.82e-06	4.02e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—colon cancer	6.68e-06	3.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—colon cancer	6.56e-06	3.87e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—colon cancer	6.31e-06	3.72e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—EP300—colon cancer	6.25e-06	3.68e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—colon cancer	5.88e-06	3.46e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—colon cancer	5.71e-06	3.37e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—colon cancer	5.57e-06	3.28e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—colon cancer	5.25e-06	3.1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—colon cancer	5.07e-06	2.99e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—colon cancer	4.67e-06	2.75e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—colon cancer	4.62e-06	2.72e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—EP300—colon cancer	4.37e-06	2.58e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—colon cancer	4.14e-06	2.44e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—colon cancer	3.78e-06	2.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—colon cancer	3.23e-06	1.91e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—colon cancer	2.64e-06	1.56e-05	CbGpPWpGaD
